ADHD Treatment
Non-Stimulant ADHD Medications: A Complete Guide
Strattera, Qelbree, Intuniv, Kapvay, and beyond — everything you need to know about treating ADHD without stimulants.
Disclaimer: This article is for educational purposes only. Medication decisions require evaluation by a licensed psychiatric provider.
When most people think about ADHD medication, stimulants like Adderall and Vyvanse come to mind first. And for good reason — stimulants are effective and fast-acting for many patients. But stimulants are not the right fit for everyone.
Non-stimulant ADHD medications offer an important alternative for patients who experience intolerable stimulant side effects, have a history of substance use disorder, struggle with significant co-occurring anxiety, or simply prefer to avoid controlled substances. In some cases, a non-stimulant may be prescribed alongside a stimulant to enhance overall treatment.
This guide covers every major non-stimulant ADHD medication currently available — how each works, who it's best for, expected side effects, and practical considerations.
When Non-Stimulants May Be Used
The decision to use a non-stimulant for ADHD is not simply a second-choice — for many patients, it is the optimal choice. Psychiatric providers consider non-stimulants as first-line options in several clinical situations:
- •Substance use history: Non-stimulants have essentially no abuse potential and are ideal when addiction history is a concern.
- •Co-occurring anxiety: Stimulants can worsen anxiety in susceptible individuals; non-stimulants (especially Strattera) may actually reduce anxious symptoms.
- •Stimulant side effects: Insomnia, appetite suppression, increased heart rate, or irritability that is severe or persistent with stimulants.
- •Cardiovascular concerns: Certain heart conditions may limit stimulant use.
- •24-hour coverage: Some patients benefit from the round-the-clock symptom management that non-stimulants provide, unlike the 10–14 hour window of most stimulants.
- •Prescription convenience: Non-controlled medications can be refilled without a monthly new prescription, making them more convenient for many patients.
FDA-Approved Non-Stimulant Options
Strattera (Atomoxetine)
FDA-approved for ADHD in ages 6+
Strattera (atomoxetine) is the most widely prescribed non-stimulant ADHD medication and the first non-stimulant to receive FDA approval specifically for ADHD (2002). It works as a selective norepinephrine reuptake inhibitor (SNRI), blocking the reuptake of norepinephrine in the prefrontal cortex to improve attention, impulse control, and executive function.
The key trade-off with Strattera is onset time: unlike stimulants that work within hours, Strattera requires 4–8 weeks of daily use to build to full therapeutic effect. This is a critical expectation to set before starting treatment. However, once effective, it provides consistent 24-hour symptom coverage — including evenings, weekends, and mornings — which many patients and families value highly.
Typical Dosing:
- • Adults: 40–100 mg/day
- • Once or twice daily
- • Take with food to reduce nausea
- • Generic widely available
Common Side Effects:
- • Nausea (especially early weeks)
- • Fatigue or drowsiness
- • Dry mouth
- • Decreased appetite (milder than stimulants)
- • Dizziness upon standing
Read the full Strattera guide → · Strattera vs Vyvanse comparison →
Qelbree (Viloxazine)
FDA-approved for ADHD in ages 6+
Qelbree (viloxazine) received FDA approval in 2021 and represents the newest non-stimulant ADHD option. Like Strattera, viloxazine is a norepinephrine reuptake inhibitor — but it has a distinct pharmacological profile that may cause fewer side effects in some patients. It was originally developed in Europe as an antidepressant before being reformulated and approved for ADHD.
Qelbree is available in extended-release capsules and reaches full therapeutic effect faster than Strattera — some studies show meaningful improvement within 2–4 weeks, though 4–8 weeks is still needed for optimal benefit. Early clinical data suggests Qelbree may have a favorable side effect profile compared to Strattera, with less nausea and sexual dysfunction reported.
Typical Dosing:
- • Adults: 200–600 mg/day
- • Once daily (morning or evening)
- • Brand name only (no generic yet)
- • Can be opened and sprinkled on food
Common Side Effects:
- • Somnolence (drowsiness)
- • Decreased appetite
- • Headache
- • Fatigue
- • Irritability
Note: Qelbree carries an FDA warning about increased risk of suicidal thoughts in children and teens, similar to Strattera.
Intuniv (Guanfacine ER)
FDA-approved for ADHD in ages 6–17
Intuniv works through an entirely different mechanism than Strattera or Qelbree — it is an alpha-2A adrenergic receptor agonist. Originally developed as a blood pressure medication (Tenex), guanfacine was found to have significant benefits for ADHD when used in extended-release form. It is FDA-approved for children and adolescents ages 6–17, and is often used off-label in adults.
Intuniv is particularly effective for ADHD symptoms related to hyperactivity, impulsivity, and emotional dysregulation — including outbursts and frustration intolerance. It is frequently used as an add-on to stimulant therapy rather than as a standalone treatment, particularly in children.
Typical Dosing:
- • Children 6–17: 1–4 mg/day
- • Adults (off-label): 1–4 mg/day
- • Once daily
- • Generic guanfacine ER available
Common Side Effects:
- • Sedation/drowsiness (especially early)
- • Low blood pressure
- • Dizziness
- • Headache
- • Stomach upset
Important: Intuniv should not be stopped abruptly — dose must be tapered to avoid rebound hypertension.
Kapvay (Clonidine ER)
FDA-approved for ADHD in ages 6–17
Kapvay (clonidine ER) is similar to Intuniv — it is also an alpha-2 adrenergic agonist originally used for blood pressure — but it acts on slightly different receptor subtypes and has a more sedating effect. It is FDA-approved for ADHD in children ages 6–17 and is used off-label in adults, often as an adjunct to stimulant therapy, particularly for managing hyperactivity and improving sleep.
Because Kapvay is more sedating than Intuniv, it is sometimes prescribed specifically at bedtime to address stimulant-induced insomnia while also providing overnight ADHD symptom benefit. It can also be helpful for children with ADHD plus tic disorders (Tourette syndrome).
Typical Dosing:
- • Children 6–17: 0.1–0.4 mg/day
- • Adults (off-label): 0.1–0.4 mg/day
- • Twice daily (morning and bedtime)
- • Generic clonidine ER available
Common Side Effects:
- • Significant sedation (especially at first)
- • Low blood pressure
- • Dry mouth
- • Dizziness
- • Constipation
Off-Label Options: Wellbutrin for ADHD
Wellbutrin (bupropion) is an antidepressant — specifically a norepinephrine-dopamine reuptake inhibitor (NDRI) — that is widely used off-label for ADHD. While it does not have an FDA indication for ADHD, multiple studies support its effectiveness, particularly for adults with ADHD who also have depression.
Bupropion's mechanism — blocking the reuptake of both dopamine and norepinephrine — overlaps with how stimulants work, which explains its ADHD benefit. It is not a controlled substance, comes in inexpensive generic form, and can simultaneously address depression and ADHD symptoms in patients with both conditions.
Wellbutrin for ADHD — Key Facts:
- • Off-label use (not FDA-approved for ADHD, but evidence-supported)
- • Not a controlled substance
- • Generic available — low cost
- • Takes 2–4 weeks to begin working; 6–8 weeks for full benefit
- • Particularly useful in ADHD + depression combination
- • May lower seizure threshold at high doses — avoid in patients with seizure history
Non-Stimulant vs Stimulant: A Quick Comparison
| Feature | Non-Stimulants | Stimulants |
|---|---|---|
| Onset of Action | 4–8 weeks | Hours to days |
| Duration of Effect | 24 hours (most) | 8–14 hours |
| Controlled Substance | No | Yes (Schedule II) |
| Abuse Potential | Negligible | Low–moderate |
| Anxiety Impact | Neutral to beneficial | May worsen anxiety |
| Overall Effectiveness | Moderate (varies) | Higher on average |
What to Expect When Starting a Non-Stimulant
The most important expectation to set when starting a non-stimulant ADHD medication is patience. Unlike stimulants — where you may notice a difference within hours — non-stimulants require consistent daily use for weeks before their benefits become apparent. This is not a sign that the medication isn't working; it's simply how these medications build their effect.
Evaluation First
Your provider will conduct a thorough ADHD evaluation, review your medical history, discuss your goals, and explain which non-stimulant option may be most appropriate for your situation. Learn about ADHD evaluation →
Low Starting Dose
Most non-stimulants are started at a low dose and gradually increased over several weeks to minimize side effects and find the optimal therapeutic dose for you.
Track Your Symptoms
Keep a simple log of your daily attention, mood, sleep, and appetite during the first 4–8 weeks. This helps your provider make evidence-based adjustments at follow-up appointments.
Regular Follow-Ups
Your provider will schedule follow-ups every 4–6 weeks during the titration phase to monitor response and side effects. Once stable, appointments typically shift to every 1–3 months.
Frequently Asked Questions
What is the most effective non-stimulant medication for ADHD?
Strattera (atomoxetine) is the most widely studied and commonly prescribed non-stimulant. However, newer options like Qelbree (viloxazine) are gaining traction. The "most effective" option varies by individual — a psychiatric provider can identify the best fit based on your symptom profile, age, and medical history.
How long do non-stimulant ADHD medications take to work?
Most non-stimulants require 4–8 weeks of daily use to show full therapeutic benefit. Some patients notice gradual improvements within 2–3 weeks, but complete benefit typically requires consistent use for at least one month. The alpha-2 agonists (Intuniv, Kapvay) may show some effect sooner, particularly for hyperactivity and sleep.
Can you treat ADHD without stimulants?
Yes. Non-stimulant medications can provide meaningful ADHD relief for many patients — particularly those who cannot tolerate stimulants, have a history of substance use disorder, or have co-occurring anxiety. While stimulants are generally more effective on average, non-stimulants are a legitimate and clinically appropriate choice in many situations.
Are non-stimulant ADHD medications controlled substances?
No. Strattera, Qelbree, Wellbutrin, Intuniv, and Kapvay are all non-controlled. They can be prescribed with standard refills without the monthly Schedule II restrictions that apply to Adderall, Vyvanse, and Concerta.
Ready to Explore Your ADHD Treatment Options?
Pinnacle BHW offers same-day ADHD evaluations via telehealth across North Carolina. Our licensed psychiatric providers will help you determine whether a stimulant, non-stimulant, or combination approach is right for you.
Published
Content is written and reviewed by licensed psychiatric providers at Pinnacle BHW following clinical guidance and peer-reviewed literature. Learn about our editorial standards →
Related Articles
- Strattera (Atomoxetine) for ADHDFull guide to Strattera — the most commonly prescribed non-stimulant ADHD medication.
- Strattera vs Vyvanse: Full ComparisonSide-by-side comparison of non-stimulant and stimulant ADHD medications.
- Signs You Have ADHD as an AdultCommon ADHD symptoms in adults that often go unrecognized and untreated.